OX40 Ligand in Asthma
A major asthma discovery by a researcher at the Institute has been licensed by MedImmune, a biotechnology company and wholly owned subsidiary of AstraZeneca PLC. MedImmune licensed the discovery to explore its use in the development of a potential biologics drug for treating asthma. Under the agreement, MedImmune was granted exclusive intellectual property rights to the discovery, which demonstrated the pivotal role of a protein called the OX40 ligand in asthma. The finding was made by the laboratory of Institute scientist Michael Croft, Ph.D., and marked a major milestone in asthma research.